ENLIGHTLens

AI-enabled Precision Drug Development

ENLIGHTLens brings ENLIGHT’s tumor intelligence to the aid of pharma/biotech drug development. Some of its applications are:

  • Novel drug target identification Genes which are at the hub of rich interaction networks (vulnerability maps) can be identified as attractive potential drug targets.
  • Optimal combination therapy search For a given new drug, Pangea finds the optimal partner drug for combination therapy by analyzing synergistic drug effects.
  • Biomarker-guided clinical trial design ENLIGHT’s precise biomarkers can guide clinical trials with optimized target population choice, including target population expansion and opening up trials in new cancer indications.

ENLIGHTMatch

Next-Generation Treatment Nomination

Based on sequencing derived from standard FFPE (Formalin Fixed, Paraffin Embedded) pathology samples, ENLIGHTMatch delivers an actionable report helping physicians to make informed treatment decisions. ENLIGHT screens dozens of treatment options, assigning each an ENLIGHT Matching Score, and presenting the results in an intuitive, easy-to-understand report, delivering concrete actionable insights to the oncologist. Each relevant drug, including on-label and off-label options, receives a category of response probability, aiding healthcare professionals to find the best treatment for each patient.
mail

We are always open for collaboration

contact us for collaboration opportunities arrow